Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Breast Cancer Reports
Erschienen in: Current Breast Cancer Reports 4/2017

03.11.2017 | Systemic Therapies (M Liu and T Haddad, Section Editors)

Treatment of Breast Cancer During Pregnancy

verfasst von: Mounica Vallurupalli, Ann H. Partridge, Erica L. Mayer

Erschienen in: Current Breast Cancer Reports | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Breast cancer during pregnancy (BCP) is an increasingly recognized entity as women delay the onset of childbearing. This review outlines multi-disciplinary approaches to the management of BCP which attempt to provide effective cancer therapy for the BCP patient, while balancing the safety of the developing fetus.

Recent Findings

Surgery may be utilized in all trimesters of pregnancy, and immediate breast reconstruction as well as sentinel lymph node biopsy is feasible. Most standard breast cancer chemotherapy can be initiated after the first trimester; however, certain treatments, including radiation, anti-human epidermal growth factor receptor 2 therapies, and hormonal therapies, should be delayed during pregnancy. Iatrogenic pre-term delivery should be avoided when possible, as it may increase complications associated with prematurity.

Summary

Data from recent large observational studies support the use of many standard breast cancer treatment paradigms in the BCP population. However, compromises and delays may arise, requiring individualization of treatment for each BCP patient. Additional research is needed to evaluate the impact of treatment delays, as well as the safety and efficacy of targeted therapies in the BCP population.
Literatur
1.
Bodner-Adler B, Bodner K, Zeisler H. Breast cancer diagnosed during pregnancy. Anticancer Res. 2007;27(3b):1705–7.PubMed
2.
Smith LH, Dalrymple JL, Leiserowitz GS, Danielsen B, Gilbert WM. Obstetrical deliveries associated with maternal malignancy in California, 1992 through 1997. Am J Obstet Gynecol. 2001;184(7):1504–12. discussion 1512-1503CrossRefPubMed
3.
Gemignani ML, Petrek JA, Borgen PI. Breast cancer and pregnancy. Surg Clin North Am. 1999;79(5):1157–69.CrossRefPubMed
4.
Psyrri A, Burtness B. Pregnancy-associated breast cancer. Cancer J (Sudbury, Mass). 2005;11(2):83–95.CrossRef
5.
6.
Lee GE, Mayer EL, Partridge A. Prognosis of pregnancy-associated breast cancer. Breast Cancer Res Treat. 2017.
7.
Sukumvanich P. Review of current treatment options for pregnancy-associated breast cancer. Clin Obstet Gynecol. 2011;54(1):164–72.CrossRefPubMed
8.
Johansson AL, Andersson TM, Hsieh CC, et al. Stage at diagnosis and mortality in women with pregnancy-associated breast cancer (PABC). Breast Cancer Res Treat. 2013;139(1):183–92.CrossRefPubMed
9.
Litton JK, Warneke CL, Hahn KM, et al. Case control study of women treated with chemotherapy for breast cancer during pregnancy as compared with nonpregnant patients with breast cancer. Oncologist. 2013;18(4):369–76.CrossRefPubMedPubMedCentral
10.
Azim HA Jr, Santoro L, Russell-Edu W, Pentheroudakis G, Pavlidis N, Peccatori FA. Prognosis of pregnancy-associated breast cancer: a meta-analysis of 30 studies. Cancer Treat Rev. 2012;38(7):834–42.CrossRefPubMed
11.
Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Res Treat. 2016;160(2):347–60.CrossRefPubMed
12.
Polyak K. Pregnancy and breast cancer: the other side of the coin. Cancer Cell. 2006;9(3):151–3.CrossRefPubMed
13.
Amant F, von Minckwitz G, Han SN, et al. Prognosis of women with primary breast cancer diagnosed during pregnancy: results from an international collaborative study. J Clin Oncol: Off J Am Soc Clin Oncol. 2013;31(20):2532–9.CrossRef
14.
Johansson AL, Andersson TM, Hsieh CC, Cnattingius S, Lambe M. Increased mortality in women with breast cancer detected during pregnancy and different periods postpartum. Cancer Epidemiol Biomark Prev. 2011;20(9):1865–72.CrossRef
15.
Callihan EB, Gao D, Jindal S, et al. Postpartum diagnosis demonstrates a high risk for metastasis and merits an expanded definition of pregnancy-associated breast cancer. Breast Cancer Res Treat. 2013;138(2):549–59.CrossRefPubMedPubMedCentral
16.
17.
Loibl S, von Minckwitz G, Gwyn K, et al. Breast carcinoma during pregnancy. International recommendations from an expert meeting. Cancer. 2006;106(2):237–46.CrossRefPubMed
18.
Loibl S, Schmidt A, Gentilini O, et al. Breast cancer diagnosed during pregnancy: adapting recent advances in breast cancer care for pregnant patients. JAMA Oncol. 2015;1(8):1145–53.CrossRefPubMed
19.
Amant F, Deckers S, Van Calsteren K, et al. Breast cancer in pregnancy: recommendations of an international consensus meeting. Eur J Cancer (Oxford, England : 1990). 2010;46(18):3158–68.CrossRef
20.
O'Neill AC, DiPiro PJ, Mayer EL. Staging workup in breast cancer patients in managing cancer in pregnancy. Switzerland: Springer International Pubishing; 2016.
21.
Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol: Off J Am Soc Clin Oncol. 2014;32(13):1365–83.CrossRef
22.
Amant F, Loibl S, Neven P, Van Calsteren K. Breast cancer in pregnancy. Lancet (London, England). 2012;379(9815):570–9.CrossRef
23.
Cordeiro CN, Gemignani ML. Breast cancer in pregnancy: avoiding fetal harm when maternal treatment is necessary. Breast J. 2017;23(2):200–5.CrossRefPubMed
24.
Viswanathan S, Ramaswamy B. Pregnancy-associated breast cancer. Clin Obstet Gynecol. 2011;54(4):546–55.CrossRefPubMed
25.
Zagouri F, Psaltopoulou T, Dimitrakakis C, Bartsch R, Dimopoulos MA. Challenges in managing breast cancer during pregnancy. J Thoracic Dis. 2013;5(Suppl 1):S62–7.
26.
Pruthi S, Haakenson C, Brost BC, et al. Pharmacokinetics of methylene blue dye for lymphatic mapping in breast cancer-implications for use in pregnancy. Am J Surg. 2011;201(1):70–5.CrossRefPubMed
27.
Krishna I, Lindsay M. Breast cancer in pregnancy. Obstet Gynecol Clin N Am. 2013;40(3):559–71.CrossRef
28.
Bezu C, Coutant C, Salengro A, Darai E, Rouzier R, Uzan S. Anaphylactic response to blue dye during sentinel lymph node biopsy. Surg Oncol. 2011;20(1):e55–9.CrossRefPubMed
29.
Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial. Lancet Oncol. 2010;11(10):927–33.CrossRefPubMedPubMedCentral
30.
Albo D, Wayne JD, Hunt KK, et al. Anaphylactic reactions to isosulfan blue dye during sentinel lymph node biopsy for breast cancer. Am J Surg. 2001;182(4):393–8.CrossRefPubMed
31.
Wahid F, Malkan A, Pappo A, Wright B, Adefeyisan S, Sandoval J. Severe anaphylactic shock due to methylene blue dye. J Pediatr Surg Case Rep. 2014;2:117–8.CrossRef
32.
Thevarajah S, Huston TL, Simmons RMA. Comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg. 2005;189(2):236–9.CrossRefPubMed
33.
Gentilini O, Cremonesi M, Trifiro G, et al. Safety of sentinel node biopsy in pregnant patients with breast cancer. Ann Oncol: Off J Eur Soc Med Oncol. 2004;15(9):1348–51.CrossRef
34.
Gropper AB, Calvillo KZ, Dominici L, et al. Sentinel lymph node biopsy in pregnant women with breast cancer. Ann Surg Oncol. 2014;21(8):2506–11.CrossRefPubMed
35.
Khera SY, Kiluk JV, Hasson DM, et al. Pregnancy-associated breast cancer patients can safely undergo lymphatic mapping. Breast J. 2008;14(3):250–4.CrossRefPubMed
36.
Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19-22, 2001, Philadelphia, Pennsylvania. Cancer. 2002;94(10):2542–51.CrossRefPubMed
37.
Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2005;23(30):7703–20.CrossRef
38.
Caragacianu DL, Mayer EL, Chun YS, et al. Immediate breast reconstruction following mastectomy in pregnant women with breast cancer. J Surg Oncol. 2016;114(2):140–3.CrossRefPubMed
39.
Lohsiriwat V, Peccatori FA, Martella S, et al. Immediate breast reconstruction with expander in pregnant breast cancer patients. Breast (Edinburgh, Scotland). 2013;22(5):657–60.CrossRef
40.
Garcia-Manero M, Royo MP, Espinos J, Pina L, Alcazar JL, Lopez G. Pregnancy associated breast cancer. Eur J Surg Oncol: J Eur Soc Surg Oncol British Assoc Surg Oncol. 2009;35(2):215–8.CrossRef
41.
Meisel JL, Economy KE, Calvillo KZ, et al. Contemporary multidisciplinary treatment of pregnancy-associated breast cancer. SpringerPlus. 2013;2(1):297.CrossRefPubMedPubMedCentral
42.
Halaska MJ, Pentheroudakis G, Strnad P, et al. Presentation, management and outcome of 32 patients with pregnancy-associated breast cancer: a matched controlled study. Breast J. 2009;15(5):461–7.CrossRefPubMed
43.
Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol: Off J Eur Soci Med Oncol. 2012;23(12):3016–23.CrossRef
44.
Loibl S, Han SN, von Minckwitz G, et al. Treatment of breast cancer during pregnancy: an observational study. Lancet Oncol. 2012;13(9):887–96.CrossRefPubMed
45.
Cardonick E, Gilmandyar D, Somer RA. Maternal and neonatal outcomes of dose-dense chemotherapy for breast cancer in pregnancy. Obstet Gynecol. 2012;120(6):1267–72.CrossRefPubMed
46.
Mir O, Berveiller P, Goffinet F, et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol: Off J Eur Soc Med Oncol. 2010;21(2):425–6.CrossRef
47.
Zagouri F, Sergentanis TN, Chrysikos D, Papadimitriou CA, Dimopoulos MA, Bartsch R. Trastuzumab administration during pregnancy: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137(2):349–57.CrossRefPubMed
48.
Pasternak B, Svanstrom H, Hviid A. Ondansetron in pregnancy and risk of adverse fetal outcomes. N Engl J Med. 2013;368(9):814–23.CrossRefPubMed
49.
Boxer LA, Bolyard AA, Kelley ML, et al. Use of granulocyte colony-stimulating factor during pregnancy in women with chronic neutropenia. Obstet Gynecol. 2015;125(1):197–203.CrossRefPubMedPubMedCentral
50.
Cardonick E, Ifran F, Torres N. The use of neupogen (filgrastim) or neulasta (pegfilgrastim) during pregnancy when chemotherapy is indicated for maternal cancer treatment. J Cancer Therap. 2012;3(2):157–61.CrossRef
51.
Perez EA, Suman VJ, Davidson NE, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol: Off J Am Soc Clin Oncol. 2011;29(34):4491–7.CrossRef
52.
Van Calsteren K, Heyns L, De Smet F, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol: Off J Am Soc Clin Oncol. 2010;28(4):683–9.CrossRef
53.
Cardonick EH, Gringlas MB, Hunter K, Greenspan J. Development of children born to mothers with cancer during pregnancy: comparing in utero chemotherapy-exposed children with nonexposed controls. Am J Obstet Gynecol. 2015;212(5):658.e651-658.CrossRef
54.
Amant F, Vandenbroucke T, Verheecke M, et al. Pediatric outcome after maternal cancer diagnosed during pregnancy. N Engl J Med. 2015;373(19):1824–34.CrossRefPubMed
Metadaten
Titel
Treatment of Breast Cancer During Pregnancy
verfasst von
Mounica Vallurupalli
Ann H. Partridge
Erica L. Mayer
Publikationsdatum
03.11.2017
Verlag
Springer US
Erschienen in
Current Breast Cancer Reports / Ausgabe 4/2017
Print ISSN: 1943-4588
Elektronische ISSN: 1943-4596
DOI
https://doi.org/10.1007/s12609-017-0256-5

Weitere Artikel der Ausgabe 4/2017

Current Breast Cancer Reports 4/2017 Zur Ausgabe

Systemic Therapies (M Liu and T Haddad, Section Editors)

Immunotherapy Approaches to Breast Cancer

Breast Cancer Screening and Imaging (HTC Le-Petross and BE Adrada, Section Editors)

DBT as a Screening Tool and a Diagnostic Tool

Systemic Therapies (M Liu and T Haddad, Section Editors)

Systemic Therapy in the Setting of Central Nervous System (CNS) Metastases in Breast Cancer

Systemic Therapies (M Liu and T Haddad, Section Editors)

Androgen Receptor-Targeted Therapy for Breast Cancer

Breast Cancer Screening and Imaging (HTC Le-Petross and BE Adrada, Section Editors)

How Effective Is Mammography as a Screening Tool?

Systemic Therapies (M Liu and T Haddad, Section Editors)

Pre-operative Endocrine Therapy

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

23.04.2024 Medikamente in Schwangerschaft und Stillzeit Nachrichten

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise